An evaluation of bimekizumab for the treatment of hidradenitis suppurativa
{{output}}
Introduction: Until recently, the biological treatment options for hidradenitis suppurativa (HS) were largely restricted to adalimumab and secukinumab. In 2024, bimekizumab, an IL-17A and IL-17F antibody was introduced to the cli... ...
